Compared with type I, papillary RCC type II more frequently carries unfavorable tumor characteristics. Papillary renal cell carcinoma (RCC) type II subtype appears to be more unfavorable and ...

Correlation of pathologic findings after brief neoadjuvant sorafenib with results of dynamic-contrast enhanced (DCE) and diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with locally ...

Clear cell RCC is the most common histologic subtype of malignant tumors of the kidney. This histology accounts for 75% of renal masses that are evaluated. 7,8 Clear cell RCC derives from the proximal ...

Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a rare, autosomal dominant syndrome characterised by the development of cutaneous and uterine leiomyomas alongside an aggressive form of ...

Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...

Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...

Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...

Please provide your email address to receive an email when new articles are posted on . Updated phase 2 data showed promising efficacy of cabozantinib plus nivolumab in patients with papillary, ...

There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in ...

A new analysis of U.S. military personnel included Black, White, and Hispanic adults newly diagnosed with primary stage I-III RCC between 1998 and 2014. Hispanic and White patients had similar rates ...